Ask about this productRelated genes to: PTGER3 antibody
- Gene:
- PTGER3 NIH gene
- Name:
- prostaglandin E receptor 3
- Previous symbol:
- -
- Synonyms:
- EP3
- Chromosome:
- 1p31.1
- Locus Type:
- gene with protein product
- Date approved:
- 1994-07-29
- Date modifiied:
- 2016-10-05
Related products to: PTGER3 antibody
Related articles to: PTGER3 antibody
- Sanjie Xiaoliu Granule (XJXLG), a traditional multi-herbal prescription widely used in Chinese medicine, has been historically applied to "disperse nodules, soothe the liver, and relieve depression." It is clinically prescribed for patients with breast lumps, emotional stagnation, and cancer-related depression. However, the pharmacological basis underlying its dual anticancer and antidepressant effects remains poorly understood.This study aimed to evaluate the therapeutic efficacy and elucidate the molecular and metabolic mechanisms of XJXLG in breast cancer with depression (BCD) through integrated experimental and bioinformatics approaches. In vivo and in vitro BCD models were established to assess tumor growth, behavioral performance, and inflammatory cytokine levels. Liquid chromatography-mass spectrometry (LC-MS) identified active constituents of XJXLG. Bioinformatics analyses were used to screen key genes and signaling pathways, followed by validation via qRT-PCR and Western blot. Untargeted metabolomics was applied to explore the metabolic alterations in tumor tissues after XJXLG intervention. - Source: PubMed
Publication date: 2026/05/18
Liu ZhuoTong TianhaoYang RenyiZeng Puhua - Fried food and hazard factors, particularly acrylamide, have been implicated in adverse health outcomes. However, how fried food consumption fuels the development of metabolic associated fatty liver disease (MAFLD) remains poorly understood. - Source: PubMed
Publication date: 2026/04/26
Wan XuzhiLiu XiaohuiMeng DenghuiWang AnliSong XiaoranHuang YingyuZhang FanLin XunanYao JianxinZheng YouyouLu QiTian YimeiFan YileiZhuang PanJiao JingjingZhang Yu - E-prostanoid 3 receptor (EP3) plays an important role in maintaining normal heart growth and development, and its activation may drive acute inflammation and influence intracellular Ca level. The effects of targeting EP3 on myocardial injury have been very controversial. We aimed to elucidate roles of EP3 in both innate immune cells and cardiomyocytes during the acute phase of acute myocardial injury. Wild-type, global Ep3 knockout (Ep3), myeloid conditional Ep3-deficient (Ep3;Lyz2) and tamoxifen-induced cardiomyocyte-specific Ep3 knockout (Ep3;Myh6) mice were subjected to regional ischemia/reperfusion (I/R) or acute doxorubicin (DOX) treatment. Inflammation, prostaglandin production, and damage-associated molecular pattern (DAMP) release were induced in acute myocardial injury in mice and patients. Injury caused by I/R or DOX was substantially ameliorated in EP3 antagonist-treated wild-types, but not in their Ep3 counterparts. I/R injury was alleviated in Ep3;Lyz2 rodents and Ep3;Myh6 mice at 1 week after the administration of tamoxifen, but exacerbated in the latter at 8 weeks. Germline Ep3 hearts were predisposed to abnormalities. Antagonism or myeloid deficiency of EP3 ameliorated I/R injury by suppressing inflammation and regulating necrosis pathways, constituting an auto-amplification loop of necroinflammation. EP3 disruption in cardiomyocytes prevented the agonist-induced increase of diastolic Ca level. Short-term EP3 abrogation in cardiomyocytes also reduced local and systemic inflammation after I/R. Collectively, long-term EP3 abrogation predisposes hearts to abnormalities and is detrimental; however, its deficiency in myeloid cells or transient deletion in cardiomyocytes convergently mitigates necroinflammation and alleviates acute myocardial injury, indicating short-term EP3 blockade is a potentially promising therapeutic strategy for such diseases. - Source: PubMed
Publication date: 2026/03/17
He DongChen YequnGe JiahuiGuo JinweiWang ZhenYu GangWu ShiwanLeng JingWang BinPang ShunyuChen XijianXu YinengPeng ChengYang JianyeLiu ShijunCai AnhongZeng ZhengpengShi XinyaLing SiyiChen YukuanZhou YingbiLiu Bin - In this issue of Cancer Cell, Ma et al. identify a neoadjuvant chemotherapy-induced population of PTGER3 cancer-associated fibroblasts (CAFs) in patients with bladder cancer. These CAFs undergo lipid oxidation reprogramming and enhance CD8 T cell function, facilitating tumor microenvironment remodeling and restraining tumor progression. - Source: PubMed
Publication date: 2026/03/05
Mahadevan Krishnan KKalluri Raghu - Renal fibrosis (RF) represents a major pathological outcome of chronic kidney disease, currently accompanied by extremely limited therapeutic strategies. To decipher key cellular and molecular drivers, we integrated single-cell and bulk transcriptomic profiles for comprehensive analysis. Based on the RF-related single-cell and bulk transcriptomic data, key cell subtypes were identified through Scissor analysis, custom signature matrix construction via CIBERSORTx, and Weighted Gene Co-Expression Network Analysis (WGCNA). Subsequently, key subtype-related biomarkers were identified through the expression analysis, and functional enrichment analysis for biomarkers was conducted to elucidate the potential mechanisms by which biomarkers regulate RF. Through comprehensive profiling, thick ascending limb (TAL) cells were predominant and displayed marked heterogeneity in renal fibrosis (RF), with cortical TAL (CTAL) and adaptive TAL (aTAL) identified as principal subtypes. A set of candidate biomarkers was identified. Quantitative polymerase chain reaction (qPCR) validation in mouse models confirmed aberrant expression of these biomarkers, with STAT1 and PARP8 upregulated and HS6ST2, PTGER3, and TMEM207 downregulated in RF. Furthermore, functional enrichment analyses indicated that these biomarkers were associated with pathways underlying metabolic reprogramming and immune perturbation. Our study implicates CTAL and aTAL as central cellular players in RF and identifies their associated biomarkers. These experimentally validated biomarkers provide novel targets and repurposing opportunities for RF therapeutic intervention. - Source: PubMed
Publication date: 2026/02/16
Wang HengpingZhang YuanLi JialeFu YingWang Huiyan